Today, the American Society for Clinical Oncology(ASCO) posted a link to the ASCO 2014 meeting planner[LINK]. The planner also includes all of the abstract titles at the meeting. ASCO 2014 is scheduled to take place from May 30th to June 3rd, 2014. Below we list some of our observations on the oral abstracts. We have […]
April 7 Biotech Update- An Active AACR
So a lot to talk about and I will briefly touch on a lot and then expand later this week as I doubt many days will be a busy as today in term of news. The sector had a good morning but we have seen this before and at this point it will not be […]
March 25 Biotech Update- Would it Help to Cry Uncle?
Today certainly started as a better day in the sector but I would be careful of chasing this move. Ideally, we spend time building a base but a day or two of running is possible given the oversold conditions in the space. At this point I would lean towards the sector having put in a […]
March 14 Biotech Update- Seeing Red as Value or the End?
Interesting morning for the sector with the broader market relatively unchanged and the biotech sector selling off hard. Why would this be the case? Is it something fundamental to the sector or just jittery traders dumping unnecessarily? Given the macro uncertainty in the Ukraine it could just be the case that traders are reducing risk […]
March 12 Biotech Update- Ovarian Cancer in the News
The broad sector continues to try and finds its footing, so there is really nothing new on that front. I want to spend this note talking about two companies that I have been receiving questions on the past couple of days. Please keep the questions coming as I want to make sure and touch on […]
Upcoming events for Merck
Members of Chimera Research Group have successfully been trading Merck for the past few months, especially Joe Gantos(@GantosJ). Merck has been one of the strongest big pharmas over the past few month on the heels of pipeline developments. With a new year, we want to provide a road map for what’s to come in the […]
February 25 Biotech Update- Some Upcoming Catalysts
It is another day with the sector trading basically in line with market and the real outperformers/underperformers have news associated with them. At this point the real tension in the sector is between the clear continuation of the rally and the fear/expectation of a larger macro correction that will take the sector down with it. […]
February 10 Biotech Update- A Choppy Start to the Week
It was a choppy and mixed morning with the market and sector looking for direction. There were winners and losers across the sector and market caps. After a large up day, it is not necessarily bad for the market to settle down to digest the move. All of that being said, if I had to […]
February 3 Biotech Update- The Bloodbath Edition
It was another rough day in the market with a familiar pattern- market weak, large cap biotechs outperforming the broader market and small cap biotechs underperforming. It makes sense in that risk off means selling biotechs but large cap biotechs have a valuation buffer in their growing free cash flow. This is not to say […]
January 31 Biotech Update- The Hep-C Competition Heats Up
The market was just a little weak this morning and biotechs responded as one would expect, although despite the sea of red I kept thinking that it could be have been worse. Today was certainly not a good day but the market is starting to provide us some good bargains. There could be a larger […]
January 27 Biotech Update
It is amazing how quickly sentiment can change. Last week I was noting the shifts and the expectations for a correction. This was certainly needed but I think the speed of the move has less to do with fundamentals and more to do with jittery investors. Nobody wants to be the last one to sell, […]
Upcoming Phase 3 trials
With a fresh start to 2014 and the biotech market still very strong, we wanted to examine some upcoming Phase 3 results that will be in focus in the first quarter. Expectations for some of these trials varies widely. We have a blend of small biotech to big pharma. Company: Merck (MRK) and Amgen (AMGN) […]
January 22nd Biotech Update
I feel like a record stuck skipping over the same part but there has not really been anything new in the market this week either from a macro sense or even at the individual level. The sector was strong in the morning basically on the backs of the large caps (see GILD later in the […]
December 18 Biotech Update- Rigorsertib Fail Pancreatic Trial (no surprise) and MRK Collaborates
We are getting into the doldrums so to speak and not much is going on. The market really seemed listless in the morning as I guess traders were waiting for the taper decision. I still see a negative bias in biotech, especially in this year’s big winners. It could very well be that funds are […]
November 25 Biotech Update- What to Make of CLDX and CBST data and the new MRK trial
The market was a low volume chop fest (although with a fairly narrow range) for the most part and I do not think we should read too much into price movements unless they really take off on above average volume. We might be able to learn something about sentiment this week but I believe that […]
November 5- EOD
The morning looked bad but the sector came back a little. There was some sporadic buying of oncology names but nothing major. It will be very interesting to see how the sector responds to the ASH abstracts. Obviously there will be winners and losers but the question in my mind is how will the PPS […]
CLDX – A look at CDX-1127
Celldex Therapeutics (CLDX) has one of the most anticipated data releases amongst small biotech companies this fall. They are scheduled to present data from their Phase 1 dose-escalation trial of a CDX-1127 (CD27, a T-cell stimulator) at the annual meeting of the Society for ImmunoTherapy of Cancer(SITC), November 7-10th. We will also likely see some […]
October 29- EOD
Well, it seemed like an odd day for the sector in that it was almost directionless. This is not to say that there were not moves among individual stocks but we are finally starting to see them move on merit and less on sector sentiment. I think this is a good sign and hopefully we […]
Datasets in focus at IASLC this weekend
This weekend is the 15th annual World Conference on Lung Cancer, sponsored by tge International Assoc. for The Study Of Lung Cancer (IASLC). It takes place Sunday October 27th through Wednesday 30th (Site). Abstracts can be found here. In particular, we want to speak briefly about 7 presentations. PD1 inhibitors Bristol-Myers (BMY), Merck (MRK) and Roche (RHHBY) […]
Merck – Quick Chart Review
Merck & Co. Inc. (MRK) -NYSE For the first time since March 1st, MRK’s price dropped below its 200-Day Moving Average. This is worth a deeper look at the price action and the indicators are showing a “Bullish Divergence” and within the oversold zone. Merck will take part at the (IASLC) the 15th World Conference on […]
